Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 11/20 | 0.43 |
| ▸ | DRD2 | P14416 | 10/20 | 0.43 |
| ▸ | DRD3 | P35462 | 9/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243305 | 0.86 | MAPT (0.48) | DRD4DRD2DRD3HTR1AADRA2C | |
| SCHEMBL4246264 | 0.82 | DRD2 (0.48) | DRD4DRD2DRD3MAPKAPK2 | |
| SCHEMBL4246064 | 0.79 | PPARD (0.42) | DRD4DRD2DRD3HTR1AHTR2A | |
| SCHEMBL4390463 | 0.78 | LRRK2 (0.45) | DRD4DRD2DRD3KDM1AHRH1 | |
| SCHEMBL4249833 | 0.75 | GPR39 (0.48) | DRD4DRD2DRD3 | |
| SCHEMBL4253037 | 0.74 | MAPT (0.60) | DRD4DRD2DRD3HTR1AHTR2A | |
| SCHEMBL4391668 | 0.74 | MAPT (0.54) | DRD4DRD2DRD3HTR1AHTR2A | |
| SCHEMBL4071799 | 0.73 | MAOB (0.50) | DRD4KDM1A | |
| SCHEMBL12204385 | 0.73 | MEN1 (0.60) | DRD4DRD2DRD3 | |
| SCHEMBL4248465 | 0.73 | SMO (0.46) | DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | claimed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | DRD4 4818/4885DRD2 4806/4885DRD3 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.